New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.
- Eli Lilly's Tirzepatide is driving 65% of the company's revenue amid intense competition in the GLP-1 market.